Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study to Identify BEnefits After 24 Weeks of NEBILET®(Nebivolol) Administration For Essential hypertensIon Patients With Various Co-morbidities and Treatment Environments in KOREA.

NCT03847350 is registered in ClinicalTrials.gov with A.Menarini Asia-Pacific Holdings Pte Ltd as lead sponsor.

NCT NCT03847350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03847350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study to Identify BEnefits After 24 Weeks of NEBILET®(Nebivolol) Administration For Essential hypertensIon Patients With Various Co-morbidities and Treatment Environments in KOREA.
Lead sponsor
A.Menarini Asia-Pacific Holdings Pte Ltd
Phase
Observational
Overall status
Completed
Start date
July 1, 2015
Completion date
March 23, 2017
Enrollment
3,250 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension